Back to news

Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years

Business Wire•19/11/2026•07:00 ET
0

Key Highlights

  • ➤FDA approves Regeneron’s Livsayis for adult anti-AChR antibody-positive generalized myasthenia gravis
  • ➤Alnylam receives $25 million approval payment from Regeneron
  • ➤Alnylam eligible for tiered double-digit royalties up to 15% on global net sales
  • ➤Livsayis becomes the first RNAi therapeutic approved for generalized myasthenia gravis
  • ➤Livsayis marks Alnylam’s seventh FDA-approved RNAi therapeutic in less than nine years

Expert Statements

Yvonne Greenstreet, Chief Executive Officer of Alnylam

“Seven FDA-approved medicines originating from Alnylam in under nine years is powerful evidence that RNAi has become an important and differentiated platform for creating new medicines.”

Yvonne Greenstreet, Chief Executive Officer of Alnylam

“Livsayis began with Alnylam science, and its approval demonstrates how our innovation can ultimately reach patients through both our own portfolio and strategic partnerships.”

Yvonne Greenstreet, Chief Executive Officer of Alnylam

“As we look ahead, we remain focused on advancing RNAi science, expanding its application to new areas of medicine, and delivering meaningful outcomes for patients.”

Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years

− First RNAi Therapeutic Approved for Generalized Myasthenia Gravis –

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in